인쇄하기
취소

Series of hepatitis B treatments enter Seoul National University Hospital, warning fierce competition

Published: 2018-02-06 15:58:49
Updated: 2018-02-06 15:58:49

As Ildong Pharmaceutical’s ‘Besivo’ entered Seoul National University Hospital January after Gilead Sciences’ ‘Vemlidy’ last December, it has notified even fiercer competition in the chronic type B hepatitis market. The two products were also landed together on Severance Hospital last November.

According to the industry concerned, the Seoul National University Hospital Drug Committee approved ...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.